Biocept, a provider of liquid biopsy tests for cancer, has announced the commercial availability of its Target Selector pan-TRK assay to detect TRK proteins.

With the assay, physicians can gain information through a simple blood sample on the potential presence of NTRK fusions, which are biomarkers used to qualify patients for treatment with TRK inhibitor therapies. TRK protein is associated with aggressive cancer in certain tumour types, such as lung cancer.

Given that sensitivity and specificity between the presence of TRK proteins and FISH detection of NTRK fusions is 95.2% and 100%, respectively, Biocept’s pan-TRK assay can be used as a method to determine the potential presence of NTRK fusions and if patients need to undergo further testing.

Biocept senior vice president and senior medical director Veena Singh said: “Biocept’s Target Selector pan-TRK assay utilises our proprietary circulating tumour cell (CTC) platform, which enables a simple blood-based test to screen for TRK gene alternations, a unique liquid biopsy offering.

“Biocept’s novel liquid biopsy tests are designed to help physicians rapidly and in real-time identify key biomarkers of interest to facilitate the clinical decision-making process.”

Following the launch of the assay, the molecular diagnostics company now provides 20 CLIA-certified liquid biopsy tests utilising its Target Selector platform that helps to ascertain the status of actionable solid tumour biomarkers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Its commercialised assays are intended for lung, breast, gastric, colorectal and prostate cancers, as well as melanoma.

Biocept president and CEO Michael Nall said: “We continue to execute on expanding our menu of non-invasive and cost-effective biomarker tests. Biocept now offers 20 commercially available liquid biopsy assays including two tumour-specific next-generation sequencing panels that cover the most actionable genomic alterations for solid tumours.

“We believe that this comprehensive offering, including the addition of our Target Selector pan-TRK test, will help us increase the adoption of our liquid biopsy platform in the oncology market.”